Director of Strategic Alliances
The Journal of Precision Medicine
Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics
Dr. Kamala K Maddali is currently Vice President, Biopharma Collaborations, Market Development and Companion Diagnostics at Cancer Genetics Inc, Rutherford, NJ. Cancer Genetics, Inc. (CGI) is a leader in the field of personalized medicine, offering diagnostic products and services that enable precision medicine in the field of oncology.
Dr. Maddali holds a DVM Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India.
Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She has promoted the proper utilization of biomarkers, personalized medicine and diagnostics in drug development and patient management to bridge the gap between drug and diagnostic industries. She was Global Director Scientific Development -Biomarkers & Companion Diagnostics for Q2 Solutions (A Quintiles & Quest Diagnostics joint venture). She brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.
John S. Mudgett, Ph.D. is owner of JsM BioScience, LLC, providing science and business development
consultation services to Biotech/Technology Platform, CRO, and Scientific Conference Planning business. Customers have included ACD Bio, focusing on the Immuno-Oncology and traditional oncology in situ tissue based diagnostics, as well as Crown Bio, focusing on Immunology services and products. His services include opportunity assessment, and science and business evaluation for client penetration into the Pharma and Biotech customer base. Activities include Sigma, SWOT, and data analysis of client sales/services performance as well as in-depth customer profiling with a goal of increasing worldwide sales.
John is also Adjunct Professor and advisor, Department of Biology and Biotechnology, and member College of Science and Health Advisory Board at William Paterson University, where he is also developing and teaching graduate courses for the MS Biotechnology graduate students.
John was Vice President, Drug Discovery Services at the Genesis Biotechnology Group. Leading the integration of all drug discovery services groups and functions at the Genesis Biotechnology Group, he brought an enthusiastic vision and decades of internal and external pharmaceutical experience to create and grow a holistic customer facing Services Company with particular emphasis on expanding their Immuno-Oncology and Oncology services. At Genesis John focused and delivered on leading the proposed integration of the three CRO companies, Science and Business Development, and Financial analysis of the potential for a combined unit to deliver value.
John was External Lead – Pharmacology, Merck Research Laboratories, a position with increasing responsibilities he held for 12 years. At Merck, he brought extensive experience in the execution of scientific, business development, managerial, financial, Lean Sigma, and IT delivery for translational BioPharma support of a diverse portfolio of programs in the global CRO arena.
John was a founding member of the GEM department, tasked with taking an entrepreneurial approach to partnering with internal research to create an inception-to-impact return on investment with external providers in the US and global arenas. John was responsible for domestic and global scientific and business development, CRO alliance management, external project management, internal-external collaborations, and delivery of pipeline supporting data for program advancement. Awarded the Merck Research Laboratories Customer Focus Award, he was recognized for bringing value and experience to both internal and external customer needs and business solutions.
Dr. Mudgett holds Doctorate and Masters degrees from The Pennsylvania State University and a B.S. with high distinction from The University of Maine. He completed postdoctoral training at Los Alamos National Laboratory, where he was awarded the Alexander Hollaender Postdoctoral Fellowship Award. He is a Six Sigma certified greenbelt, and led an effort that returned $30 million to Merck in efficiencies, while increasing the scientific deliverables.
John serves as a Scientific Advisor to the Panel of Scientific Consultants for the International Mouse Phenotyping Consortium (IMPC), funded by the NIH Common Fund. He also serves as a member of the Scientific Advisory Board for PHENOMIN, the French National Infrastructure for Mouse Phenogenomics. In addition, John is a member of the BioPharma Research Council committee for helping to organize speakers and conference sessions for upcoming events focused on oncology companion diagnostics. John and his wife Kristine are actively involved in Preschool Advantage, a charitable organization serving children and families of need in obtaining quality preschool access and tuition. In addition, John has established a business providing custom wood-crafted products and services to customers throughout the US and Europe (JsM Woodcraft). John is on LinkedIn, at [www.linkedin.com/in/jsmBioScience